Physiological Responses to Daily Use of Beta-Three Adrenergic Receptor Agonist, Mirabegron
O'MARA A, CYPESS A, CERO C, JOHNSON J, LINDERMAN J, LEITNER B, FLETCHER L, BRYCHTA R, KAPURIA D, MCGEHEE S, ROTMAN Y. Physiological Responses to Daily Use of Beta-Three Adrenergic Receptor Agonist, Mirabegron. Diabetes 2018, 67 DOI: 10.2337/db18-1146-p.Peer-Reviewed Original ResearchRate-pressure productNon-esterified fatty acidsBrown adipose tissueSerum non-esterified fatty acidsCold exposureWeeks of treatmentBAT metabolic activityHealthy female volunteersAdrenergic receptor agonistPET/CTΒ3-adrenergic receptor agonistDaily mirabegronCardiovascular stimulationPrimary endpointSecondary endpointsChronic treatmentBAT volumeLiver steatosisMetabolic healthPressure productTreatment optionsInsulin sensitivityPharmacotherapeutic approachesReceptor agonistAcute effects